Citations 1310

Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set

Alzheimer Disease & Associated Disorders | October 30, 2018 | Volume: 32 | Issue: 4 | Pages: 351-358

10.1097/wad.0000000000000279 | PMID 30376508

Introduction: In 2015, the US Alzheimer’s Disease Centers (ADC) implemented Version 3 of the Uniform Data Set (UDS). This paper describes the history of Version 3 development and the UDS data that are freely available to researchers. Methods: UDS Version 3 was developed after years of coordination between the National Institute on Aging-appointed Clinical Task Force (CTF), clinicians from ∼30 ADCs, and the National Alzheimer’s Coordinating Center (NACC). The CTF recognized the need for updates to align with the state of the science in dementia research, while being flexible to the diverse needs and diseases studied at the ADCs. Version 3 also developed a nonproprietary neuropsychological battery. Results: This paper focuses on the substantial Version 3 changes to the UDS forms related to clinical diagnosis and characterization of clinical symptoms to match updated consensus-based diagnostic criteria. Between March 2015 and March 2018, 4820 participants were enrolled using UDS Version 3. Longitudinal data were available for 25,337 of the 37,568 total participants using all UDS versions. Discussion: The results from utilization of the UDS highlight the possibility for numerous research institutions to successfully collaborate, produce, and use standardized data collection instruments for over a decade.
Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43

JAMA Neurology | October 26, 2018 | Volume: 75 | Issue: 11 | Pages: 1347

10.1001/jamaneurol.2018.3139 | PMID 30422173

P4‐373: PROSTATE CANCER, USE OF ANDROGEN DEPRIVATION THERAPY AND COGNITIVE IMPAIRMENT

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.197

P4‐319: CLINICAL FEATURES, CSF BIOMARKERS, MOLECULAR IMAGING, AND PATHOLOGY IN DYSEXECUTIVE ALZHEIMER'S DISEASE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.142

P4‐318: PET MEASUREMENTS OF PHF TAU BURDEN IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE AND NO COPIES OF THE APOE4 ALLELE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.141

P4‐288: DETAILS OF THE NEW ALZHEIMER'S ASSOCIATION BEST CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION OF NEURODEGENERATIVE COGNITIVE BEHAVIORAL SYNDROMES, ALZHEIMER'S DISEASE AND DEMENTIAS IN THE UNITED STATES

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_30 | Pages: No page available

10.1016/j.jalz.2018.07.110

P4‐236: STRUCTURAL EQUATION MODELLING REVEALS A DIRECT AND INDIRECT EFFECT OF APOE ε4 ON TAR DNA BINDING PROTEIN 43

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_29 | Pages: No page available

10.1016/j.jalz.2018.07.057

P4‐232: AUTOMATING CEREBRAL MICROBLEED DETECTION IN SUPPORT OF ALZHEIMER'S DISEASE TRIALS USING A CONVOLUTIONAL NEURAL NETWORK AI

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_29 | Pages: No page available

10.1016/j.jalz.2018.07.053

O2‐14‐06: DIFFERENCES BETWEEN SPORADIC AND FAMILIAL BEHAVIORAL VARIANT FTD IN ADVANCING RESEARCH AND TREATMENT FOR FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2018.06.2723

O2‐14‐02: THE CLINICAL SPECTRUM OF FRONTOTEMPORAL LOBAR DEGENERATION IN NORTH AMERICA: BASELINE CHARACTERISTICS OF THE FIRST 912 PARTICIPANTS FROM THE ADVANCING RESEARCH AND TREATMENT IN FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2018.06.2719